17th week of 2011 patent applcation highlights part 34 |
Patent application number | Title | Published |
20110097303 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONS - A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving the systemic antiviral effect. | 2011-04-28 |
20110097304 | COMPOSITIONS AND METHODS FOR REDUCING THE LIKELIHOOD OF SPONTANEOUS ABORTION IN RECIPIENTS OF ARTIFICAL INSEMINATION - Methods and kits for preventing or reducing the likelihood of spontaneous abortion in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF). | 2011-04-28 |
20110097305 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors - Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-me-dialed disorders, such as cancer. The subject compounds arc gem-disubstituted or spimcyclic pyridine, pyrimidine and triazine derivatives. | 2011-04-28 |
20110097306 | ORAL FORMULATIONS OF CLADRIBINE - Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine. | 2011-04-28 |
20110097307 | Compositions and Methods for Augmenting Kidney Function - The present invention provides a nutritional food product composed of a prebiotic and an isolated protein for use in reducing elevated levels of nitrogenous waste products in the blood and ameliorating renal failure. | 2011-04-28 |
20110097308 | STEM CELLS TREATED BY IN VITRO FUCOSYLATION AND METHODS OF USE - A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an α1,3-fucosyltransferase, e.g., α1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other ligands on the cell surface into functional forms that bind selectins, especially P-selectin or E-selectin. The treated cells have enhanced effectiveness in reconstituting bone marrow in patients in need of such therapy. | 2011-04-28 |
20110097309 | Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue - The present inventors assessed the possibility that bone marrow-derived cells are mobilized to the grafted skin from nonskin tissues and contribute to skin tissue regeneration during the engraftment of grafted skin on biological tissues. As a result, the present inventors for the first time in the world demonstrated that: | 2011-04-28 |
20110097310 | ANTI-AGING OR ANTIOXIDANT COMPOSITION CONTAINING PLANT STEM CELL LINE DERIVED FROM CAMBIUM OF PANAX GINSENG - The present invention relates to an anti-aging or antioxidant composition which contains, as an active ingredient, a plant stem cell line derived from the cambium of | 2011-04-28 |
20110097311 | COMPOSITION HAVING BIOCIDE ACTIVITY FOR AQUEOUS PREPARATIONS - The present invention refers to a process for bacterial stabilizing aqueous preparations like e.g. calcium carbonate slurries and a composition which can be used for the biocidal treatment of such aqueous preparations. | 2011-04-28 |
20110097312 | ANTI-CANCER VACCINES - The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as immunogenic compositions for treating and/or preventing breast cancer in an individual. In specific aspects, PR1 peptide or a derivative thereof, or a myeloperoxidase peptide, or a cyclin E1 or E2 peptide is provided in methods and compositions for breast cancer treatment and/or prevention. Such peptides can be used to elicit specific CTLs that preferentially attack breast cancer based on overexpression of the target protein cells. | 2011-04-28 |
20110097313 | Method for the Identification and Separation of Non-regulatory T-cells from a Mixture of Regulatory T-cells - The present invention relates to a method of identifying and separating non-regulatory T-cells (conventional T-cells) from a mixture comprising regulatory T-cells by using of the CD154 molecule (CD40 ligand) through depletion of CD154+ T-cells from the mixture or in combination with additional positive selection of Treg using markers that are specific for regulatory T-cells, such as for example, CD25, GITR, CTLA4 or markers which are specific for activated regulatory T-cells, such as, for example, CD137, “latent TGF-beta (LAP)”, GARP (LRRC32), CD121a/b, thereby generating a cell composition of activated Treg cells. The invention relates also to a kit comprising an antibody for detecting CD154 and at least one additional antibody for detecting markers for activated or non-activated regulatory T-cells. The antibodies can be coupled to a fluorescent dye or magnetic microparticles. | 2011-04-28 |
20110097314 | METHOD FOR PRODUCING A COMPOSITION FOR PROMOTING SURVIVAL OF TRANSPLANTED HEMATOPOIETIC STEM CELL - HLA matched activated lymphocytes in mononuclear cells separated from peripheral blood or umbilical cord blood are proliferated and activated. After separating and collecting, the HLA matched activated lymphocytes are employed as the main component of a composition for promoting survival of transplanted hematopoietic stem cells. The obtained composition is widely usable in, for instance, prevention of survival failure of transplanted hematopoietic stem cells and therapy for promoting the survival thereof. Although the dose of the composition varies depending on the age, conditions, etc. of a patient, a humanized antibody is administered in a dose of from 0.2 to 20 ml/kg/day to mammals including humans. The composition is administered by intravenous injection either once a day (single administration or continuous administration) or intermittently once to 3 times in a week or once in 2 or 3 weeks. | 2011-04-28 |
20110097315 | Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-- hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer - This invention relates to the enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-43-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one, prodrugs thereof, and pharmaceutically acceptable salts and solvates of said compounds and said prodrugs, that are useful in the treatment of hyperproliferative diseases, such as cancers, in mammals. The invention also relates to processes for the production of enantiomerically pure or optically enriched (+)- or (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one enantiomers from a mixture containing two enantiomers using continuous chromatography. The invention further relates to the L-(+)-tartaric acid or (S)-(−)-1,1′-binapthyl-2,2′-diyl hydrogenphosphate salts of (+)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one. | 2011-04-28 |
20110097316 | COMPOSITION TO BE ABSORBED THROUGH MUCOUS TISSUE - The invention relates to a composition to be absorbed via mucous tissue, containing at least one hormone cleavable by proteinases and at least one proteinase or mixture of proteinases, where the at least one hormone is kept separate from the proteinase or mixture of proteinases in the composition, and furthermore to the use of the composition and to a kit for administering the composition. | 2011-04-28 |
20110097317 | Thioredoxin Interacting Protein (TXNIP) As Regulator Of Vascular Function - The present invention relates to screening assays for the identification of agents that can modify the interaction of thioredoxin interacting protein (TXNEP) on thioredoxin (TRX)5 preferably by inhibiting TXNIP downregulation of TXR. The use of such compounds, including the disclosed siRNA and antibodies against TXNIP, is contemplated for therapeutic or prophylactic treatment of vascular disease conditions, particularly those associated with pro-inflammatory activity of the TNF- ASK1-JNK-p38 pathways. | 2011-04-28 |
20110097318 | Solid-State Protein Formulation - Provided are systems comprising delivery vehicles for the stable storage of immobilized proteins, e.g., protein therapeutics, in a form amenable to administration, such as by injection or infusion, in combination with an elution fluid. Also provided are proteins adsorbed to chromatography media in a form compatible with a one-step administration of the protein. Exemplary delivery vehicles are pre-filled syringes and pre-filled infusion modules; exemplary proteins are antibodies useful in therapy. Also provided are methods of producing the immobilized proteins and methods of using the immobilized proteins, e.g., protein therapeutics. | 2011-04-28 |
20110097319 | Antibody Capable of Binding Specifically to AB-Oligomer, and Use Thereof - The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease. | 2011-04-28 |
20110097320 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF - This invention relates to novel 4-aminoquinazolines, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the EGFR and HER-2. | 2011-04-28 |
20110097321 | COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLT1 ANTAGONIST FOR TREATING CANCER - The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists. | 2011-04-28 |
20110097322 | PARTIALLY LOADED ANTIBODIES AND METHODS OF THEIR CONJUGATION - A protein containing one or more activatable groups, e.g., an antibody, is subjected to partial or complete reduction of one or more such bonds to form reactive groups; the resulting protein is reacted with a drug which is reactive with some of the reactive groups, such as certain radiometals, chelating agents, and toxins, so as to form a conjugate useful in, e.g., in vitro diagnosis, in vivo imaging, and therapy. | 2011-04-28 |
20110097323 | Her2/neu-Specific Antibodies and Methods of Using Same - This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease. | 2011-04-28 |
20110097324 | COMPOSITIONS AND METHODS FOR MODULATING NICOTINIC/NMDA RECEPTOR FUNCTION - The present invention provides a method for modulating nicotinic/NMDA receptor function in a mammal in need of such treatment comprising administering a therapeutically effective amount of an agent that disrupts heterodimerization of α | 2011-04-28 |
20110097325 | Modulation of T cell Differentiation for the treatment of T helper cell mediated diseases - The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype or the Th2 subtype, based on the relative expression levels of the gene TCCR, and its agonists or antagonists. The present invention further relates to a method of diagnosing Th1- and Th2-mediated diseases. | 2011-04-28 |
20110097326 | ANTI-TRKB ANTIBODIES - The present invention provides improved antibodies or antigen-binding molecules that specifically recognize and agonize the tyrosine receptor kinase B (TrkB) receptor, and methods of their use. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors. | 2011-04-28 |
20110097327 | PRODUCT AND METHOD FOR TREATMENT OF CONDITIONS ASSOCIATED WITH RECEPTOR-DESENSITIZATION - Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods. | 2011-04-28 |
20110097328 | METHODS AND COMPOSITIONS FOR INCREASING THE ACTIVITY OF INHIBITORY RNA - The invention provides methods for increasing the activity of an inhibitory RNA (RNAi) in a subject requiring administering one or more poly-ADP-ribose polymerase (PARP) inhibitors and/or one or more PARG activators to the subject. The invention also provides methods for increasing the activity of an inhibitory RNA in a cell or cell population requiring contacting a cell or cell population with one or more PARP inhibitors and/or one or more PARG activators. The invention further provides compositions and kits containing one or more PARP inhibitors and/or one or more PARG activators. | 2011-04-28 |
20110097329 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND MODULATING STRESS GRANULE FORMATION - The invention provides methods for treating or decreasing the likelihood of developing a stress-granule related disorder and/or cancer by administering one or more poly-ADP-ribose polymerase (PARP) inhibitors, one or more PARP activators, one or more poly-ADP-ribose glycosylase (PARG) activators, and/or one or more poly-ADP-ribose glycohydrolase ARH3 activators. The invention also provides corresponding methods of decreasing stress granule formation and/or proliferation in a cell or a population of cells. The invention further provides methods of increasing the number of stress granules and proliferation in a cell or a population of cells by administering one or more PARP activators, one or more PARP inhibitors, one or more PARG inhibitors, and/or one or more ARH3 inhibitors. The invention also provides methods for screening for agents for treating or decreasing the likelihood of developing a stress granule-related disorder or cancer, and methods for determining the propensity for developing a stress granule-related disorder or cancer, as well as compositions and kits containing one or more PARP inhibitors, one or more PARP activators, one or more PARG activators, and one or more ARH3 activators. | 2011-04-28 |
20110097330 | Novel Gene Disruptions, Compostitions and Methods Relating Thereto - The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO179, PRO181, PRO244, PRO247, PRO269, PRO293, PRO298, PRO339, PRO341, PRO347, PRO531, PRO537, PRO718, PRO773, PRO860, PRO871, PRO872, PRO813, PRO828, PRO1100, PRO1114, PRO115, PRO1126, PRO1133, PRO1154, PRO1185, PRO1194, PRO1287, PRO1291, PRO1293, PRO1310, PRO1312, PRO1335, PRO1339, PRO2155, PRO1356, PRO1385, PRO1412, PRO1487, PRO1758, PRO1779, PRO1785, PRO1889, PRO90318, PRO3434, PRO3579, PRO4322, PRO4343, PRO4347, PRO4403, PRO4976, PRO260, PRO6014, PRO6027, PRO6181, PRO6714, PRO9922, PRO7179, PRO7476, PRO9824, PRO19814, PRO19836, PRO20088, PRO70789, PRO50298, PRO51592, PRO1757, PRO4421, PRO9903, PRO1106, PRO1411, PRO1486, PRO1565, PRO4399 or PRO4404 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities. | 2011-04-28 |
20110097331 | ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation. | 2011-04-28 |
20110097332 | Composition and Method of Use for HCV Immunization - Isolated HCY E2 kinase phospho-peptides that contain one or more immunogenic fragments of a HCV E2 kinase motif and antibodies which are cross-reactive with the isolated HCV E2 kinase phospho-peptides are provided. Also disclosed are pharmaceutical compositions and/or methods to passively and/or actively immunize against HCV using the isolated HCY E2 kinase phospho-peptides and antibodies. | 2011-04-28 |
20110097333 | THERAPEUTIC AND DIAGNOSTIC AGENTS - The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides molecules having structural features characteristic of immunoregulatory signalling (IRS) molecules and which are expressed by cells of haematopoietic lineages such as, in particular, leukocytes. The molecules of the present invention find broad application inter alia as diagnostic markers for cells, targets for cell therapy and as validated drug targets in order to modulate the immune response and to treat, prevent and diagnose a range of diseases conditions including cancer, genetic disease, inflammatory conditions and conditions associated with aberrant haematopoietic cell function or activity. The present invention extends to binding partners of the instant molecules such as, for example, antibodies, ligands, adaptor and other signalling associated molecules, agonists and antagonists and to methods of screening for same. | 2011-04-28 |
20110097334 | Novel Marker Genes for Regulatory T Cells from Human Blood - The present invention provides novel marker genes for the specific identification and characterization of human suppressive and/or regulatory T cells including natural, adaptive, and expanded CD4 | 2011-04-28 |
20110097335 | ABC TRANSPORTER PROTEIN EXPRESSION INHIBITOR - Provided is a novel drug which exhibits excellent effect of inhibiting expression of an ABC transporter protein, as well as improved safety. | 2011-04-28 |
20110097336 | Methods for modulating mannose content of recombinant proteins - The present invention relates to methods of modulating (e.g., reducing) the mannose content, particularly high-mannose content of recombinant glycoproteins. | 2011-04-28 |
20110097337 | Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells - The present invention relates to a composition for eliciting a specific cytotoxic T lymphocyte (CTL) response against T cell epitopes in a mammal, which comprises a compound provoking lymphocytopenia, a molecule having selective affinity for professional antigen presenting cells (APC), wherein said molecule is associated to said T cell epitope, and optionally, a pharmaceutical acceptable carrier. Advantageously, the composition further contains an adjuvant. Said composition may be used in anti-infections and anti-cancer therapies. | 2011-04-28 |
20110097338 | Use of Substances for Sensitization of Tumor Cells to Radiation and/or Chemotherapy - The invention relates to the use of substances to increase the sensitivity of tumor cells to treatment with radiation and/or chemotherapy. This is accomplished through the use of substances which block or limit the function of the PINCH-1 protein for sensitization of tumor cells to radiation and/or chemotherapy. | 2011-04-28 |
20110097339 | Compositions monovalent for CD28 binding and methods of use - The disclosure relates to a monovalent polypeptide domain which specifically binds CD28, as well as to an antagonist of CD28, where the antagonist comprises a monovalent polypeptide domain which specifically binds CD28. This disclosure encompasses monovalent polypeptide domains comprising an antibody single variable domain that monovalently binds CD28. An antibody single variable domain that is monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a monovalent anti-CD28 antibody single variable domain consists of or comprises an antibody single variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the monovalent anti-CD28 antibody single variable domain is a human antibody single variable domain. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a monovalent anti-CD28 antibody single variable domain to the individual. | 2011-04-28 |
20110097340 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING - Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro. | 2011-04-28 |
20110097341 | Treatment of Chronic Prostatitis - The present invention relates to the use of an anti-NGF antibody in the treatment or prevention of pain and/or a lower urinary tract symptom (LUTS) associated with chronic prostatitis and/or chronic pelvic pain syndrome. | 2011-04-28 |
20110097342 | BINDING AGENTS - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. | 2011-04-28 |
20110097343 | DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES - The present invention relates to the field of diagnosis and therapy of hematological malignancies based on the tumor antigen FMR1NB (also called NY-SAR-35, Cancer/testis antigen 37 or Fragile X mental retardation 1 neighbor protein) and agents specifically targeting this antigen or cells expressing the same, e.g., antibodies. The inventors were able to prove that the molecule is expressed on the cell surface and thus represents a particularly advantageous target in cancer therapy and vaccination. Surprisingly, FMR1NB was found to be associated with hematological malignancies, e.g. acute myeloid leukemia (AML) or chronic myeloid leukemia (CML). | 2011-04-28 |
20110097344 | Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions - The present invention provides compositions and methods useful in the diagnosis and treatment of autoimmunity-related disorders, including cancers and other disorders involving angiogenesis, as well as non-cancer disorders involving a dysfunction in the immune system. In some embodiments, the invention described a plasma assay. In other embodiments, urine assay. In certain other embodiments, the invention provides therapeutic methods comprising removing toxic autoantibodies from the circulation of a patient, e.g., via plasmapheresis, and subsequently infusing the patient with one or more immunoglobulins or immunoglobulin complexes to restore the immune system of the patient to a baseline status whereby the patient's restored immune system either eliminates the source of the disorder (e.g., in the case of cancers) or no longer causes the disease or disorder (e.g., in the case of autoimmune disorders such as multiple sclerosis, psoriasis, latent autoimmune type 1 diabetes in adults (LADA) and the like). Methods of making the high activity IVIG preparation are also provided. | 2011-04-28 |
20110097345 | NOVEL DOSING REGIMEN AND METHOD OF TREATMENT - This invention relates to a method of treatment and dosing regimen for treating disease, such as cancer and mammalian tumors, wherein therapy with a cytotoxic drug is suitable, by the administration of an antibody-toxin conjugate, such as a maytansinoid toxin, by infusion at an initial infusion rate of 1 mg/min or lower on a schedule selected from the group consisting of: (1) an amount of at least about 90 mg/m | 2011-04-28 |
20110097346 | Dendritic Cells - The present invention relates to dendritic cell loaded with at least one nucleic acid molecule encoding a tumor associated antigen protein or fragment thereof and at least one tumor associated antigen protein or fragment thereof. | 2011-04-28 |
20110097347 | Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) - The present invention discloses (1) phenolic ester hybrids of niacin with m-methoxy-p-hydroxy phenyl compounds like eugenol, vanillin, apocynin, ferulic acid, isoferulic acid and eugenol epoxide and (2) cocrystals of hybrids as above, particularly cocrystal of niacin-eugenol hybrid with cocrystal former like eugenol and oxalic acid (3) novel pharmaceutical compositions comprising a combination of niacin and one or more small molecule/potentiating agent like eugenol, curcumin, cinnamic acid, meclofenamic acid, and their use in the treatment of a disorder or a disease caused by excess production of amyloid beta peptide-42 (Aβ42), its deposition, accumulation, and plaque formation including Alzheimer's Disease, dementia and mild cognitive impairment as well as other neurodegenerative diseases such as Parkinson's Disease and ischemic stroke. | 2011-04-28 |
20110097348 | Protein Formulation - A composition comprises a biological molecule that is susceptible to aggregation, dimerisation or hydrolysis, wherein the ionic strength is less than 40 mM. | 2011-04-28 |
20110097349 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R | 2011-04-28 |
20110097350 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS - Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided. | 2011-04-28 |
20110097351 | COMPOUNDS FOR TREATING BETA-AMYLOIDOSES - The present invention relates to the use of mimotopes in the treatment of diseases associated with β-amyloid formation and/or aggregation (β-Amyloidoses) including Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to Aβ1-40/42, AβpE3-40/42, Aβ3-40/42 and Aβ11-40/42. | 2011-04-28 |
20110097352 | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions - This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection. | 2011-04-28 |
20110097353 | POULTRY VIRAL MATERIALS AND METHODS RELATED THERETO - The present invention provides materials and methods for researching poultry viruses, particularly for researching infectious bronchitis viruses in poultry. Also provided are materials and methods useful for reducing the economic impact that infectious bronchitis disease has on poultry production. In one aspect of the invention, there are provided nucleic acids, amino acids and related materials and compositions useful for combating infectious bronchitis virus in poultry. | 2011-04-28 |
20110097354 | SYSTEM FOR THE EXPRESSION OF PEPTIDES ON THE BACTERIAL SURFACE - Expression system of peptides on the bacterial surface characterised in that membrane-binding region the conserved sequence of the MSP1a protein of | 2011-04-28 |
20110097355 | VIRUS-LIKE PARTICLES AS VACCINES FOR PARAMYXOVIRUS - The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines. | 2011-04-28 |
20110097356 | ANTI-INFLAMMATORY AND ANTIOXIDANT COSMETIC COMPOSITION CONTAINING GREEN TEA POLYSACCHARIDE AND TRICHOLOMA MATSUTAKE EXTRACT - Disclosed herein is a cosmetic composition which can inhibit skin aging resulting from external harmful environmental factors such as UV light and environmental pollution, which promote aging. More specifically, disclosed is a cosmetic composition, which contains green tea polysaccharide and | 2011-04-28 |
20110097357 | BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS - The present invention is directed to a bioconjugate vaccine, such as an 01-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X—N—Z—S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps. | 2011-04-28 |
20110097358 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) - Respiratory syncytial virus (RSV) virus-like particles (VLPs) comprising at least one RSV protein are described. Also described are compositions comprising these VLPs as well as methods of making and using these VLPs. | 2011-04-28 |
20110097359 | Production of diphtheria toxin | 2011-04-28 |
20110097360 | STREPTOCOCCUS PNEUMONIAE PILUS ANTIGENS - Polypeptides from | 2011-04-28 |
20110097361 | METHOD OF INDUCING TOLERANCE TO AN ALLERGEN - The present invention relates generally to the field of allergies. More particularly, the present invention provides a method for treating an allergy in a subject by inducing tolerance to an allergen associated with the allergy. Medicinal kits useful in protocols to induce tolerance or reduce intolerance in a subject also form part of the present invention. | 2011-04-28 |
20110097362 | Transmucosal Administration of Aggregated Antigens - The present invention relates to modulation of the immune response in a mammal. In particular, the invention relates to methods of inducing oral tolerance and systemic immunity in a mammal. The invention sets forth methods and compositions useful in inducing oral tolerance and systemic immunity in a mammal. | 2011-04-28 |
20110097363 | Therapeutically Effective Preparations of Insulin - The present invention provides a preparation of a therapeutically effective amount of insulin with a concentration of A21 desamido insulin greater than about 2% (w/w). | 2011-04-28 |
20110097364 | MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: | 2011-04-28 |
20110097365 | S-TRIAZINE DERIVATIVES CONTAINING AT LEAST TWO PARTICULAR SILANE AMINOBENZOATE OR SILANE AMINOBENZAMIDE GROUPS; PHOTOPROTECTIVE COSMETIC COMPOSITIONS CONTAINING THESE DERIVATIVES; USES OF THE SAID S-TRIAZINE DERIVATIVES - The invention relates to novel s-triazine derivatives containing at least two particular silane aminobenzoate or silane aminobenzamide groups and to their cosmetic uses. The invention also relates to photoprotective compositions comprising s-triazine derivatives containing at least two particular grafted silane aminobenzoate or silane aminobenzamide groups as sunscreens that are active in the UV-B radiation range. | 2011-04-28 |
20110097366 | GONIOCHROMATIC/LIGHT REFLECTIVE COSMETIC MAKEUP COMPOSITIONS - Goniochromatic/light reflecting cosmetic compositions well suited for making up the skin, lips, hair or integuments, contain (a) at least one goniochromatic coloring agent and (b) an amount of light reflective particles different from said at least one goniochromatic coloring agent and selected from the group consisting of (i) particles of a natural or synthetic substrate at least partially coated with at least one layer of at least one metal, (ii) particles of a synthetic substrate at least partially coated with at least one layer of at least one metallic compound, (iii) particles which comprise a stack of at least two layers of materials having different refractive indices, at least one of such layers optionally comprising a polymer, and (iv) metal oxide particles, formulated into (c) a topically applicable, physiologically acceptable medium therefor. | 2011-04-28 |
20110097367 | MONOLITHIC IN-SITU CROSS-LINKED ALGINATE IMPLANTS - A method of making and using a monolithic alginate implant is described. The implant is formed by providing an uncrosslinked, highly pure and high molecular weight alginate solution and injecting the alginate solution into a patient at a predetermined site to form a gel body comprising the monolithic alginate implant. Spontaneous crosslinking of the monolithic alginate implant occurs at the predetermined site without the addition of an exogenous crosslinker. The implant may be used for treating medical conditions requiring support of sphincter musculature, reconstructive surgery, or cosmetic reconstruction, for the treatment of wrinkles on the hand, face, or décolleté, or for increasing volume, for example in the case of (HIV-induced) lipoatrophy of the breasts, and for the treatment of selected diseases, including gastrooesophageal reflux disease, urinary incontinence or vesicoureteral reflux disease. | 2011-04-28 |
20110097368 | Treatment Varnish Compositions for Teeth Surfaces - Embodiments of the present invention include compositions, methods, and systems for providing an effective and efficient treatment varnish for teeth. For example, embodiments of the present invention provide a treatment varnish that comprises one or more polymers and/or copolymers that are soluble in biocompatible solvents, such as ethanol. The polymers and/or copolymers are nontoxic and form a substantially clear film that adheres effectively to teeth during treatment, but also is easily removed from teeth once the treatment is complete. | 2011-04-28 |
20110097369 | Particulate Detergent Additive - Laundry-detergent and cleaning-product additives in particle form, comprising a water-soluble or water-dispersible carrier and active ingredient microcapsules. These particles allow a user to obtain particular advantages with respect to fragrancing and care of the articles treated in conventional laundering and cleaning operations, such as, in particular, in automatic laundering of fabrics. | 2011-04-28 |
20110097370 | ANTIMICROBIAL COMPOSITION, ANTIMICROBIAL BRUSH FILAMENTS AND PREPARATION METHOD THEREOF - Disclosed is a method for preparing an antimicrobial composition for making filament for brushes. The method comprises steps in the following order: (1) mechanically pulverizing a polymer to obtain a polymer powder; (2) blending the polymer powder obtained in step (1) with an antimicrobial agent comprising phosphate, or glass, micropowder loaded with silver, zinc, or a silver-zinc composite. | 2011-04-28 |
20110097371 | Process Of Making A Stable Aqueous Dispersion Of Concentrated, Finely Divided Particles Of A Biocide - This invention provides a process of making a stable aqueous dispersion including concentrated, finely divided particles of a water insoluble biocide active, which comprises grinding the biocide in water in the presence of a non-ionic polymeric dispersant and optionally a co-dispersant, and compositions prepared by this process. | 2011-04-28 |
20110097372 | DEVICES, METHODS, AND COMPOSITIONS FOR CONTROLLING INFECTIONS - The subject invention provides novel and highly effective methods and devices for convenient and effective wound irrigation. | 2011-04-28 |
20110097373 | BONE PROSTHETIC MATERIAL AND METHOD OF MANUFACTURING THE SAME - A method of manufacturing a bone prosthetic material, includes by forming tricalcium phosphate (TCP) particle precursor particles; by performing preliminary sintering on the TCP precursor particles at a temperature in a first temperature range to produce TCP particles of diameters in a predetermined diameter range; by granulating the TCP particles to produce granulated bodies; and by performing sintering on the granulated bodies at a temperature in a second temperature range to generate sinter assemblies. The second temperature range is higher than the first temperature range. In the bone prosthetic material manufactured thus, a first space in a range of 100 to 400 μm is formed between adjacent two of a plurality of sintered assemblies. Each of the plurality of sintered assemblies includes tricalcium phosphate (TCP) particles which are subjected to sintering, and a second space in a range of 5 to 100 μm is formed between adjacent two of the TCP particles. The second space communicates with the first space. Each of the plurality of sintered assemblies has a connection portion connecting the TCP particles, and the connection portion has a width in a range of 5 to 20 μm. | 2011-04-28 |
20110097374 | Methods and Devices for Correcting Spinal Deformity With Pharmaceutical-Eluting Pedicle Screws - A method of correcting spinal deformity, which includes locating pharmaceutical-loaded implants adjacent to targeted spinal growth plates, and then eluting the pharmaceutical onto the growth plates. Preferably, the method involves correcting spinal deformity by simply inserting a pharmaceutical-eluting pedicle screw onto the concave side of a scoliotic curve. The screw has a cannulated internal reservoir that contains a chondrocyte growth-inducing pharmaceutical (such as a growth factor or small molecule) and at least one fenestration that allows the pharmaceutical to elute onto the vertebral body growth plate. | 2011-04-28 |
20110097375 | FORMULATION FOR PREVENTING OR REDUCING BLEEDING AT A SURGICAL SITE - An implantable drug depot useful for preventing, reducing or treating bleeding at a surgical site beneath the skin in a patient is provided. The implantable drug depot comprises a therapeutically effective amount of clonidine or a pharmaceutically acceptable salt thereof, and at least one biodegradable polymer. The drug depot is capable of releasing clonidine or a pharmaceutically acceptable salt thereof over a period of at least three days. | 2011-04-28 |
20110097376 | RADIOPAQUE INJECTABLE NUCLEUS HYDROGEL COMPOSITIONS - A composition suitable for use as replacement material for all or part of a disc nucleus during percutaneous injection, the composition comprising:
| 2011-04-28 |
20110097377 | Methods and Devices for Correcting Spinal Deformity With Pharmaceutical-Eluting Pedicle Screws - A method of correcting spinal deformity, which includes locating pharmaceutical-loaded implants adjacent to targeted spinal growth plates, and then eluting the pharmaceutical onto the growth plates. Preferably, the method involves correcting spinal deformity by simply inserting a pharmaceutical-eluting pedicle screw onto the concave side of a scoliotic curve. In some embodiments, the screw has a cannulated internal reservoir that contains a growth-inhibiting pharmaceutical (such as a tetracycline) and at least one fenestration that allows the pharmaceutical to elute onto the vertebral body growth plate. | 2011-04-28 |
20110097378 | DECELLULARIZED LIVER FOR REPAIR OF TISSUE AND TREATMENT OF ORGAN DEFICIENCY - The present invention provides a liver-derived devitalized mammalian parenchymatous tissue composition which includes an interstitial structure of connective tissue which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous tissue composition can further include the basement membrane of the tissue. | 2011-04-28 |
20110097379 | DIRECTED STEM CELL RECRUITMENT - The invention is directed to methods of inducing cell recruitment and tissue regeneration at a target site in a subject. It is also based, in part, on the discovery that a subject's own biologic resources and environmental conditions can be used for in situ tissue regeneration and thereby reduce or eliminate the need for donor cell procurement and ex vivo manipulation of such donor cells. Methods are disclosed for recruitment of a subject's own stem cells to a target region by inducing a sustained positive pressure at a target site, such as the kidney, thereby increasing the number of pluripotent cells capable of differentiating to regenerate the target tissue. | 2011-04-28 |
20110097380 | CLONIDINE FORMULATIONS HAVING ANTIMICROBIAL PROPERTIES - Antimicrobial clonidine compositions are provided. These antimicrobial clonidine compositions can be applied to medical devices or be part of a drug depot. Through the administration of an effective amount of clonidine at or near a target site, one can reduce, prevent, or treat infections. When appropriate clonidine compositions are provided within biodegradable polymers, the infection may be treated for extended periods of time. | 2011-04-28 |
20110097381 | CONFORMABLE TISSUE REPAIR IMPLANT CAPABLE OF INJECTION DELIVERY - A conformable tissue implant is provided for use in repairing or augmenting a tissue defect or injury site. The tissue implant contains a tissue carrier matrix comprising a plurality of biocompatible, bioresorbable granules and at least one tissue fragment in association with the granules. The tissue fragment contains one or more viable cells that can migrate from the tissue and populate the tissue carrier matrix. Also provided is a method for injectably delivering the tissue implant. | 2011-04-28 |
20110097382 | METHODS AND KITS FOR REDUCING THE LIKELIHOOD OF IMPLANTATION FAILURE AND PREGNANCY-RELATED DISORDERS IN RECIPIENTS OF ARTIFICIAL INSEMINATION - Methods and kits for preventing or reducing the likelihood of implantation failure and pregnancy-related disorders in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF). | 2011-04-28 |
20110097383 | APPARATUS AND METHODS FOR ENZYMATIC ESCHAROTOMY IN BURN INDUCED COMPARTMENT SYNDROME - Apparatus suitable for use in the prevention and treatment of burn induced compartment syndrome facilitates the rapid and efficient deployment of enzymatic compositions to the affected limb or limbs of a burn victim suffering from a circumferential burn. The apparatus includes a flexible, water-impermeable generally cylindrical covering layer. The covering layer has an inner surface facing the limb and an outer surface. The covering layer has a proximal sealable open end through which the burned limb is inserted and a distal closed end. An enzymatic escharotomy agent is contained within the covering layer. The covering layer retains the enzymatic escharotomy agent in close proximity to the burned limb, and the apparatus is enclosed within a sterile sealed package evacuated from moisture. In use, the burned limb is enclosed within the apparatus, and the enzymatic escharotomy agent is activated in situ by contacting the agent with hydrating fluid, thereby inducing enzymatic escharotomy of the circumferential burn. | 2011-04-28 |
20110097384 | TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING - A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer. | 2011-04-28 |
20110097385 | Delivery System for Drug and Cell Therapy - A method of lowering blood glucose in a mammal includes administering orally or by injection or inhalation a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin or other therapeutic agents. | 2011-04-28 |
20110097386 | STABILIZED GLUCAGON SOLUTIONS - A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so as not to induce or to minimize site irritation. The combination of a simple sugar and an surfactant stabilizes the glucagon molecule in an aqueous solution for seven days at 37° C. | 2011-04-28 |
20110097387 | PARTICULATE DRUG CARRIERS AS DESENSITIZING AGENTS - The present invention provides methods for desensitization for prevention or diminishing hypersensitivity reactions including C activation-related pseudoallergy (CARPA) and other reactions to particulate medicines. The desensitization is performed via pretreatment using a drug-free vehicle or carrier to eliminate or diminish the clinical symptoms of hypersensitivity. | 2011-04-28 |
20110097388 | Methods of Expressing Proteins with Disulfide Bridges - This invention relates to methods of expressing eukaryotic proteins in prokaryotic hosts, particularly eukaryotic proteins that require formation of disulfide bridges for biological activity. Various approaches are used including fusion to thioredoxin, cytoplasmic expression of disulfide isomerases, deficiencies in thioredoxin and/or glutathione reductases, deficiencies in proteases, and the like. The method is applicable to express monomeric and dimeric forms of the eukaryotic protein with biological activity such as monomeric and dimeric forms of a disintegrin or a disintegrin domain. Included are the vectors, host cells expressing the proteins, the expressed proteins and methods of using the proteins. | 2011-04-28 |
20110097389 | P53 BIOMARKERS - The present invention relates to the identification of p | 2011-04-28 |
20110097390 | Ultra-Small RNAs as Toll-Like Receptor-3 Antagonists - Provided are methods and compositions for the treatment or prevention of macular degeneration or other diseases or disorders associated with activation of TLR | 2011-04-28 |
20110097391 | Phospholipid Emulsion Containing Dihydroquercetin, and Method of Producing Thereof - This present invention relates generally to the field of chemistry, food industry, cosmetics, and pharmaceutical industry. More specifically, the present invention relates to liposomal biologically active forms and methods of producing thereof. The present invention provides a stable phospholipid emulsion based on dihydroquercetin (DHQ), its compounds and derivatives. The invention further provides a method a quite simple and economic method for the preparation of disclosed emulsion. The disclosed emulsion is characterized by the improved bioavailabilty and selectivity of the effect of active compounds and by the increased stability and prolonged storage terms. The claimed result is achieved using a phospholipid emulsion containing DHQ, its compounds and/or derivatives, at least one membrane-forming phospholipid, at least one zwitter-ion amino acid base, aminoacetic ether, and aqueous ethanol in the following ratio of components (wt %): Dihydroquercetin, 0.01-3; Phospholipid, 0.15-10; Zwitter-ion amino acid base, 0-8; Aminoacetic ether, 0-4; Aqueous ethanol solution (with ethanol concentration within 0.05-20%), 75-98.84. | 2011-04-28 |
20110097392 | ANTIBODY BOUND SYNTHETIC VESICLE CONTAINING MOLECULES FOR DELIVER TO CENTRAL AND PERIPHERAL NERVOUS SYSTEM CELLS - A process is provided of delivering at least one active agent cargo molecule into an neuronal cell whereby a cargo molecule is placed within a synthetic vesicle such as a liposome and a biotinylated protein such as an antibody is bound to the synthetic vesicle to form a protein bound synthetic vesicle whereby the protein recognizes a receptor expressed on the surface of a neuronal cell, and exposing the protein bound synthetic vesicle to the cell until the cargo molecule is delivered into the neuronal cell. Numerous cargo molecules are delivered by the inventive synthetic vesicle including a calpain inhibitor and a caspase inhibitor. The protein illustratively targets a cellular receptor for a ligand such as glutamate, glycine, dopamine, nicotine, muscarine, acetylcholine, or serotonin, and the like. | 2011-04-28 |
20110097393 | Skin Patches and Sustained-Release Formulations Comprising Lofexidine for Transdermal and Oral Delivery - This invention relates to a sustained release oral and transdermal pharmaceutical formulations and delivery systems comprising lofexidine. The invention is also directed to methods of treatment comprising administering lofexidine in a sustained release manner. Such methods can involve administration of the lofexidine containing compositions described herein. Compositions of lofexidine formulated for sustained release delivery are provided. Also provided are methods for the treatment of opiate addicts, migraine, neuropathic pain, and other therapeutic indications related to lofexidine. The methods may provide treatment for a variety of conditions amenable to amelioration by lofexidine administration. The methods utilize lofexidine compositions formulated for transdermal and sustained release oral delivery for administration of lofexidine in an amount effective for the treatment of the drug indications. | 2011-04-28 |
20110097394 | TYPE A GELATIN CAPSULE CONTAINING PUFA IN FREE ACID FORM - A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life. | 2011-04-28 |
20110097395 | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use - The present invention is directed to oral pharmaceutical compositions of buprenorphine and it pharmaceutically acceptable salts and the use thereof. | 2011-04-28 |
20110097396 | PEELING CAPSULE WITH INTEGRATED CARE EFFECT - A cosmetic capsule which can be topically applied and rubbed in and comprises a casing material and a filling material enclosed by the casing material. The casing material is composed of an emulsion which comprises one or more waxes that are solid above 25° C. and the filling material comprising a preparation which has an abrasive effect and comprises one or more abrasive peeling agents which are present in an oil or lipid mixture, a surfactant-containing preparation or an emulsion. | 2011-04-28 |
20110097397 | BREAK RESISTANT GEL CAPSULE - A gelatin capsule is disclosed that is designed to impart less tensile stress on the component parts when it is in the closed position and experiences less spontaneous breakage particularly when fill with hygroscopic liquids. The gelatin capsule comprises a cap portion and a body portion. The cap portion includes an annular ring and the body portion includes an annular groove. Together, the annular ring and the annular groove comprise a locking ring, which are designed to reduce the capsule cap and body contact force and stress raisers. The invention includes a cap locking ring inner diameter that is same as body locking ring outer diameter or slightly smaller to make the contacting force at the locking ring lower than current capsule designs. The body portion also includes a tapered ring configured such that, in the closed position the rim of the body portion does not contact the cap portion. | 2011-04-28 |
20110097398 | REDUCTION OF CROSS-LINKING GELATIN IN GELATIN CAPSULES - The invention relates to compositions and methods for reducing cross-linking in the gelatin shell of gelatin capsules by incorporation of free amino acid into the capsule shell and by inclusion of an ester of carboxylic acid either into the capsule filling, and/or into the capsule shell and/or into the lubrication agent, or in combinations thereof. Described are soft gelatin capsules characterized by improved stability as compared with gelatin capsules that do not contain amino acid in the shell and carboxylic acid ester in the filling, shell or in the lubrication agent, or in combinations thereof. | 2011-04-28 |
20110097399 | FAST DISSOLVING/DISINTEGRATING COATING COMPOSITIONS - A pharmaceutical composition for oral administration comprising a core and a film coating on the core that exhibits enhanced disintegration characteristics is disclosed. The film coating comprises a film forming polymer, an organic solvent, a super-disintegrant and, optionally, an acid labile material. | 2011-04-28 |
20110097400 | MAGNESIUM SYSTEM AND USE THEREOF IN THE COSMETICS INDUSTRY - A magnesium-based system suitable for use in skincare comprises (a) a first magnesium source in the form of a progressive-release oral tablet exhibiting in vitro, after 2 h in 0.1N HCl medium, a rate of dissolution (δ) of the magnesium contained therein of less than or equal to 60% by weight relative to the total weight of the Mg provided by the first magnesium source, and (b) a second magnesium source in a topical preparation. A method for treating skin for stress, fatigue or skin barrier deficiencies, as well as for stratum corneum hydration, includes orally and topically administering magnesium sources (a) and (b), respectively. | 2011-04-28 |
20110097401 | METHODS FOR TREATING GASTROINTESTINAL DISORDERS - Provided herein are compositions and formulations suitable for the treatment of gastrointestinal disorders. Also provided are methods for treating, preventing, or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus. | 2011-04-28 |
20110097402 | NON-ADHESIVE ELASTIC GELATIN MATRICES - The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix is a lyophilized mixture of protein(s), polymer(s), cross-linking agent(s) and optional plasticizer(s). The invention also provides methods for making the non-adhesive elastic gelatin matrix. | 2011-04-28 |